We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+5%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$40.3B
AUM Growth
+$535M
(+1.3%)
Cap. Flow
-$468M
Cap. Flow
% of AUM
-1.16%
Top 10 Holdings %
Top 10 Hldgs %
15.78%
Holding
2,279
New
170
Increased
711
Reduced
1,071
Closed
189
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$178M |
| 2 |
LyondellBasell Industries
LYB
|
+$133M |
| 3 |
AT&T
T
|
+$124M |
| 4 |
Stanley Black & Decker
SWK
|
+$101M |
| 5 |
Pfizer
PFE
|
+$93.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Clorox
CLX
|
+$229M |
| 2 |
Gilead Sciences
GILD
|
+$164M |
| 3 |
Broadcom
AVGO
|
+$149M |
| 4 |
KeyCorp
KEY
|
+$145M |
| 5 |
Darden Restaurants
DRI
|
+$125M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.22% |
| 2 | Technology | 14.47% |
| 3 | Financials | 10.84% |
| 4 | Industrials | 9.01% |
| 5 | Consumer Discretionary | 8.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1176
Genpact
G
$5.93B
| $864K | ﹤0.01% |
23,003
-688
| -3% | -$27.7K |
|
|
WRK
1177
DELISTED
WestRock Company
WRK
| $863K | ﹤0.01% |
29,701
-694
| -2% | -$20.1K |
|
1178
KRONOS Worldwide
KRO
$936M
| $863K | ﹤0.01% |
98,858
-4,202
| -4% | -$37K |
|
1179
GameStop
GME
$11.1B
| $862K | ﹤0.01% |
35,539
-1,074
| -3% | -$24.1K |
|
1180
Capri Holdings
CPRI
$1.67B
| $862K | ﹤0.01% |
24,012
+5,765
| +32% | +$229K |
|
|
NARI
1181
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $859K | ﹤0.01% |
14,778
+7,595
| +106% | +$479K |
|
|
DCH
1182
Dauch Corp
DCH
$1.43B
| $853K | ﹤0.01% |
103,193
-2,836
| -3% | -$21K |
|
1183
Universal Display
OLED
$3.51B
| $853K | ﹤0.01% |
5,919
-557
| -9% | -$79.8K |
|
1184
Brighthouse Financial
BHF
$2.81B
| $848K | ﹤0.01% |
17,910
-467,762
| -96% | -$20.1M |
|
|
ODP
1185
DELISTED
ODP
ODP
| $842K | ﹤0.01% |
17,978
+6,653
| +59% | +$286K |
|
1186
Coherent
COHR
$56.8B
| $841K | ﹤0.01% |
16,500
-4,176
| -20% | -$155K |
|
1187
Fox Factory Holding Corp
FOXF
$812M
| $837K | ﹤0.01% |
7,718
+677
| +10% | +$69.3K |
|
1188
Tiptree Inc
TIPT
$653M
| $837K | ﹤0.01% |
55,758
+440
| +0.8% | +$6.12K |
|
1189
Acco Brands
ACCO
$392M
| $822K | ﹤0.01% |
157,787
+8,087
| +5% | +$40.7K |
|
1190
Protagonist Therapeutics
PTGX
$9.24B
| $821K | ﹤0.01% |
29,727
+74
| +0.2% | +$1.85K |
|
1191
Arteris
AIP
$1.03B
| $818K | ﹤0.01% |
120,000
| – | – |
|
1192
Coastal Financial
CCB
$694M
| $818K | ﹤0.01% |
21,730
-390
| -2% | -$13.9K |
|
1193
SEI Investments
SEIC
$12.6B
| $817K | ﹤0.01% |
13,706
-521
| -4% | -$30.3K |
|
1194
Harmony Biosciences
HRMY
$2.46B
| $815K | ﹤0.01% |
23,173
-15,363
| -40% | -$530K |
|
1195
Gentex
GNTX
$4.7B
| $814K | ﹤0.01% |
27,833
-1,039
| -4% | -$28.6K |
|
1196
Inogen
INGN
$136M
| $814K | ﹤0.01% |
70,458
-350,917
| -83% | -$4.14M |
|
1197
Wolfspeed
WOLF
$1.25B
| $812K | ﹤0.01% |
14,612
-1,028
| -7% | -$52.4K |
|
1198
Avis
CAR
$4.13B
| $802K | ﹤0.01% |
3,506
-1,087
| -24% | -$199K |
|
1199
Option Care Health
OPCH
$3.67B
| $800K | ﹤0.01% |
24,633
-9
| -0% | -$271 |
|
1200
Arcus Biosciences
RCUS
$3.14B
| $800K | ﹤0.01% |
39,368
+34,915
| +784% | +$665K |
|
Similar funds
Federated Hermes's Q2 2023 Portfolio in Review
As of Q2 2023, Federated Hermes held 2,279 positions worth $40.3B, up 1.3% from $39.7B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Federated Hermes's Q2 2023 filing shows 170 new, 711 increased, 1,071 reduced and 189 closed positions. Its largest new stake was HashiCorp, Inc. Class A Common Stock: 1,317,400 shares worth $34.5M. The largest sale was Clorox, an estimated $229M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 20% a quarter earlier, followed by Technology and Financials.
- Federated Hermes's largest Q2 2023 buy was HashiCorp, Inc. Class A Common Stock: 1,317,400 shares worth $34.5M.
- Federated Hermes added most to Amgen in Q2 2023, an estimated $178M increase.
- Federated Hermes's biggest Q2 2023 reduction was Clorox, cutting an estimated $229M.
- Federated Hermes fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $55.4M.
- Federated Hermes's ten largest holdings make up 16% of its $40.3B portfolio in Q2 2023.
- Federated Hermes opened 170 new positions and closed 189 in Q2 2023.
- Federated Hermes's portfolio value rose 1.3% quarter-over-quarter to $40.3B.
Based on Federated Hermes's 13F filing for Q2 2023, filed 14 Aug 2023.